Paul F Jacobson Net Worth

The estimated Net Worth of Paul F Jacobson is at least $1.15 Milion dollars as of 22 October 2008. Paul Jacobson owns over 62,500 units of Progenics Pharmaceuticals stock worth over $514,960 and over the last 22 years Paul sold PGNX stock worth over $637,050.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Paul Jacobson PGNX stock SEC Form 4 insiders trading

Paul has made over 3 trades of the Progenics Pharmaceuticals stock since 2005, according to the Form 4 filled with the SEC. Most recently Paul sold 62,500 units of PGNX stock worth $577,500 on 22 October 2008.

The largest trade Paul's ever made was selling 62,500 units of Progenics Pharmaceuticals stock on 22 October 2008 worth over $577,500. On average, Paul trades about 8,389 units every 136 days since 2003. As of 22 October 2008 Paul still owns at least 125,600 units of Progenics Pharmaceuticals stock.

You can see the complete history of Paul Jacobson stock trades at the bottom of the page.

What's Paul Jacobson's mailing address?

Paul's mailing address filed with the SEC is 432 PEA POND ROAD, , BEDFORD, NY, 10506.

Insiders trading at Progenics Pharmaceuticals

Over the last 22 years, insiders at Progenics Pharmaceuticals have traded over $11,559,939 worth of Progenics Pharmaceuticals stock and bought 2,672,016 units worth $11,900,148 . The most active insiders traders include Healthcare Master Fund Ltd ..., Michael D Kishbauch oraz Bradley L Campbell. On average, Progenics Pharmaceuticals executives and independent directors trade stock every 16 days with the average trade being worth of $60,241. The most recent stock trade was executed by Capital, L.P.Altiva Managem... on 9 September 2019, trading 72,023 units of PGNX stock currently worth $359,395.

What does Progenics Pharmaceuticals do?

Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon in 1986 and is headquartered in New York, NY.

Complete history of Paul Jacobson stock trades at Progenics Pharmaceuticals

Progenics Pharmaceuticals executives and stock owners

Progenics Pharmaceuticals executives and other stock owners filed with the SEC include:

• Partners, Llc Melkonian Cap...,
  
• Nicole Williams,
  Director
• Healthcare Master Fund Ltd ...,
  
• Healthcare Master Fund Ltd ...,
  
• Sheldon Hirt,
  Executive VP & General Counsel
• Michael D Kishbauch,
  Director
• David A Scheinberg,
  Director
• Karen Jean Ferrante,
  Director
• Peter J Crowley,
  Director
• Bradley L Campbell,
  Director
• Jeffery Summer,
  SVP, Digital Technology
• Patrick Fabbio,
  CFO
• Mark Robert Baker,
  CEO
• Charles A Baker,
  Director
• Kurt W Briner,
  Director
• Stephen P Goff,
  Director
• Mark F Dalton,
  Director
• Thomas A Boyd,
  SR. VP, Product Development
• Paul F Jacobson,
  Director
• Robert A Mckinney,
  VP of Finance and Admin
• Alton B Kremer,
  VP, Clinical Research
• Robert J Israel,
  Senior VP Medical Affairs
• Philip K Yachmetz,
  VP, Gen Counsel and Secretary
• Ronald J Prentki,
  President
• William C Olson,
  Senior VP, Research and Develo
• Paul J Maddon,
  Director
• Angelo William Jr Lovallo,
  Vice President Finance
• Hagop Youssoufian,
  Executive Vice President R&D
• Capital, L.P.Altiva Managem...,
  
• Heinz Christoph Maeusli,
  Director
• Gerard Ber,
  Director
• Ann L. Mac Dougall,
  Director
• Eric J Ende,
  Director
• Vivien Wong,
  EVP, Development
• David W. Mims,
  Interim CEO and Interim CFO
• Bryce Tenbarge,
  SVP, Commercial
• Benedict Osorio,
  COO
• Asha Das,
  Chief Medical Officer